First-in-Human Study of IMGC936 in Participants With Advanced Solid Tumors

NCT04622774 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

56

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor

Interventions

DRUG: IMGC936

Sponsor

ImmunoGen, Inc.

Collaborators

[object Object]